ArticleThe Journal of allergy and clinical immunology2025
Effects of inflammatory endotypes on disease trajectory in chronic rhinosinusitis with nasal polyps.
Article in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Correlation of Local Nasal Biomarkers and Olfactory Dysfunction in Chronic Rhinosinusitis: A Systematic Review and Meta-Analysis.International forum of allergy & rhinology · 2026Pooled it
- ATP/P2X7 signaling as a potential predictive biomarker for early recurrence of nasal polyps: Correlation with inflammasome activation and epithelial barrier dysfunction.The World Allergy Organization journal · 2026Article
- Biomarker Axes, Detection Limits, and Endotype Stability in CRS: Reply to Katkuri et al. and Hong.International forum of allergy & rhinology · 2026Article
- Beyond type 2 inflammation: An innate-myeloid axis is linked to recurrence of chronic rhinosinusitis with nasal polyps.The Journal of allergy and clinical immunology · 2026Article
- Comprehensive proteomic analysis reveals SPRR3 as an early predictive biomarker for postoperative recurrence in pediatric chronic rhinosinusitis with nasal polyps.The World Allergy Organization journal · 2026Article
- Improvement of Mixed Inflammatory Environment in Nasal Secretions of Diffuse Type 2 Chronic Rhinosinusitis With Nasal Polyps Under Dupilumab.Clinical and translational allergy · 2026Article
- What can we learn about chronic rhinosinusitis through mucus?Current opinion in otolaryngology & head and neck surgery · 2026Review
- Development and validation of a nomogram based on LASSO regression for predicting early postoperative polyp recurrence in patients with chronic rhinosinusitis with nasal polyps.Frontiers in surgery · 2026Article
- Predictive Modeling of Surgically Recalcitrant Chronic Rhinosinusitis Using Integrated Feature Sets.Ear, nose, & throat journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlthough phenotypic features have traditionally guided treatment in chronic rhinosinusitis, recent research has favored categorization on the basis of inflammatory endotype. However, the impact of endotypic differeces on clinical outcomes remains largely unknown.
objectiveWe sought to compare disease trajectory, primarily time-to-polyp recurrence, between chronic rhinosinusitis with nasal polyp (CRSwNP) endotypes.
methodsSamples were obtained from patients with CRSwNP undergoing surgery between 2015 and 2023, and cytokine levels were measured using a multiplex bead assay. Principal-component analysis followed by hierarchical cluster analysis was used to identify endotype clusters. Clinical outcomes were subsequently compared between clusters.
resultsSix CRSwNP disease clusters were identified among the 269 included patients. Cluster 1 (46.5%) was characterized by relatively low inflammation. Cluster 4 (13.3%) and cluster 6 (7.1%) also exhibited low inflammation but with elevated levels of IL-12/IL-21 and CCL5, respectively. Cluster 2 (4.5%) represented a mixed type 1/3 inflammatory endotype (IFN-γ
conclusionsThe study highlights the heterogeneous nature of CRSwNP and differences in disease trajectory between endotypes, notably that patients with mixed type 1 and type 3 inflammation demonstrate more recalcitrant disease. These findings suggest that therapies beyond traditional type 2 inflammation treatments may be needed to effectively reduce CRSwNP disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.